Latest Articles
Cartherics secures Japanese patent to bolster cell therapy push - PharmaDispatch
Cartherics secures Japanese patent to bolster cell therapy push PharmaDispatch
Published: June 10, 2026, 12:17 a.m.
The RUBY trial: For certain patients, immunotherapy-chemo combination keeps advanced endometrial cancer from progressing for years - MSN
The RUBY trial: For certain patients, immunotherapy-chemo combination keeps advanced endometrial cancer from progressing for years MSN
Published: June 8, 2026, 8:37 p.m.
Women ‘blindsided’ as critical hormone therapy pulled from shelves - Herald Sun
Women ‘blindsided’ as critical hormone therapy pulled from shelves Herald Sun
Published: June 4, 2026, 8:38 p.m.
FOCL: Robotic focal therapy growth accelerates with HIFU innovation, new indications, and global expansion - TradingView
FOCL: Robotic focal therapy growth accelerates with HIFU innovation, new indications, and global expansion TradingView
Published: June 4, 2026, 7:18 p.m.
Women ‘blindsided’ as critical hormone therapy pulled from shelves - NT News
Women ‘blindsided’ as critical hormone therapy pulled from shelves NT News
Published: June 4, 2026, 4:21 a.m.
Women ‘blindsided’ as critical hormone therapy pulled from shelves - The Cairns Post
Women ‘blindsided’ as critical hormone therapy pulled from shelves The Cairns Post
Published: June 4, 2026, 4:20 a.m.
Addition of Pembrolizumab to Chemotherapy Continues to Demonstrate Overall Survival Benefit in Advanced or Recurrent Endometrial Cancer - The ASCO Post
Addition of Pembrolizumab to Chemotherapy Continues to Demonstrate Overall Survival Benefit in Advanced or Recurrent Endometrial Cancer The ASCO Post
Published: June 3, 2026, 2:49 p.m.
NRG-GY018 at ASCO 2026: Pembrolizumab Plus Chemotherapy Sustains Overall Survival Benefit in Advanced Endometrial Cancer - Oncodaily
NRG-GY018 at ASCO 2026: Pembrolizumab Plus Chemotherapy Sustains Overall Survival Benefit in Advanced Endometrial Cancer Oncodaily
Published: June 3, 2026, 3:15 a.m.
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer - MSN
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer MSN
Published: June 2, 2026, 12:41 a.m.
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer - Medical Xpress
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer Medical Xpress
Published: June 1, 2026, 8 p.m.
Link copied to clipboard!